Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.
Seong SJ, Lim M, Sohn SK, Moon JH, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, Bang SM, Jung CW, Kim DH, Park SY, Yoon SS, Kim I, Lee HG, Won JH, Min YH, Cheong JW, Park JS, Eom KS, Hyun MS, Kim MK, Kim H, Park MR, Park J, Kim CS, Kim HJ, Kim YK, Park EK, Zang DY, Jo DY, Lee HW, Yoon YR. Seong SJ, et al. Among authors: joo yd. Ann Oncol. 2013 Mar;24(3):756-60. doi: 10.1093/annonc/mds532. Epub 2012 Oct 31. Ann Oncol. 2013. PMID: 23117072 Free article.
Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
Koh Y, Kim I, Yoon SS, Kim BK, Kim DY, Lee JH, Lee KH, Park E, Kim HJ, Sohn SK, Joo YD, Kim SJ, Chung J, Shin HJ, Kim SH, Kim CS, Song HS, Kim MK, Hyun MS, Ahn JS, Jung CW, Park S; Korean Society of Hematology CML working party. Koh Y, et al. Among authors: joo yd. Ann Hematol. 2010 Jul;89(7):725-31. doi: 10.1007/s00277-010-0910-8. Epub 2010 Feb 24. Ann Hematol. 2010. PMID: 20179930 Clinical Trial.
Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.
Sohn SK, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, Bang SM, Jung CW, Kim DH, Yoon SS, Kim H, Lee HG, Won JH, Min YH, Cheong JW, Park JS, Eom KS, Hyun MS, Kim MK, Kim H, Park MR, Park J, Kim CS, Kim HJ, Kim YK, Park EK, Zang DY, Jo DY, Moon JH, Park SY. Sohn SK, et al. Among authors: joo yd. Leuk Lymphoma. 2011 Jun;52(6):1024-9. doi: 10.3109/10428194.2011.563885. Epub 2011 Apr 4. Leuk Lymphoma. 2011. PMID: 21463107 Clinical Trial.
GSTT1 copy number gain is a poor predictive marker for escalated-dose imatinib treatment in chronic myeloid leukemia: genetic predictive marker found using array comparative genomic hybridization.
Koh Y, Kim DY, Park SH, Jung SH, Park E, Kim HJ, Sohn SK, Joo YD, Kim SJ, Shin HJ, Kim SH, Song HS, Chung J, Kim I, Yoon SS, Kim BK, Shin SH, Chung YJ, Park S. Koh Y, et al. Among authors: joo yd. Cancer Genet Cytogenet. 2010 Dec;203(2):215-21. doi: 10.1016/j.cancergencyto.2010.08.022. Cancer Genet Cytogenet. 2010. PMID: 21156236
Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients.
Kim I, Koh Y, Yoon SS, Park S, Kim BK, Kim DY, Lee JH, Lee KH, Cheong JW, Lee HK, Kim SH, Kim H, Joo YD, Lee SM, Won JH, Park SK, Hong DS, Kim SH, Sohn SK, Kim CS, Park E, Kim MK, Park MR, Lee JH, Min YH; Korean Society of Hematology AML/MDS working party. Kim I, et al. Among authors: joo yd. Am J Hematol. 2013 Jan;88(1):10-5. doi: 10.1002/ajh.23337. Epub 2012 Oct 17. Am J Hematol. 2013. PMID: 23077109 Free article. Clinical Trial.
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.
Kim DY, Joo YD, Lim SN, Kim SD, Lee JH, Lee JH, Kim DH, Kim K, Jung CW, Kim I, Yoon SS, Park S, Ahn JS, Yang DH, Lee JJ, Lee HS, Kim YS, Mun YC, Kim H, Park JH, Moon JH, Sohn SK, Lee SM, Lee WS, Kim KH, Won JH, Hyun MS, Park J, Lee JH, Shin HJ, Chung JS, Lee H, Eom HS, Lee GW, Cho YU, Jang S, Park CJ, Chi HS, Lee KH; Adult Acute Lymphoblastic Leukemia Working Party of the Korean Society of Hematology. Kim DY, et al. Among authors: joo yd. Blood. 2015 Aug 6;126(6):746-56. doi: 10.1182/blood-2015-03-636548. Epub 2015 Jun 11. Blood. 2015. PMID: 26065651 Free article. Clinical Trial.
Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia.
Lee SM, Lee WS, Shin HJ, Lee JJ, Sohn SK, Moon JH, Eom HS, Won JH, Lee KH, Lee JH, Kim DY, Yoon SS, Kim I, Jung CW, Kim SJ, Kim H, Lee JH, Ryoo HM, Lee GW, Kim SH, Mun YC, Kim MK, Joo YD; Korean Society of Hematology Adult ALL working party. Lee SM, et al. Among authors: joo yd. Ann Hematol. 2013 Aug;92(8):1101-10. doi: 10.1007/s00277-013-1728-y. Epub 2013 Apr 5. Ann Hematol. 2013. PMID: 23558905 Clinical Trial.
Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment.
Shin HJ, Kim HJ, Sohn SK, Min YH, Won JH, Kim I, Yoon HJ, Lee JH, Jo DY, Joo YD, Jung CW, Lee KH; Korean Society of Hematology, AML/MDS Working Party; Chung JS, Ahn JS, Kim SJ, Lee JH, Choi SJ, Lee JH, Bae SH, Hong DS, Zang DY, Kim SH, Lee JL, Bang SM. Shin HJ, et al. Among authors: joo yd. Jpn J Clin Oncol. 2010 Jun;40(6):556-66. doi: 10.1093/jjco/hyq007. Epub 2010 Feb 25. Jpn J Clin Oncol. 2010. PMID: 20185460
Comparison between matched related and alternative donors of allogeneic hematopoietic stem cells transplanted into adult patients with acquired aplastic anemia: multivariate and propensity score-matched analysis.
Kim H, Kim BS, Kim DH, Hyun MS, Kim SH, Bae SH, Choi JH, Sohn SK, Shin HJ, Won JH, Yoon SS, Jo DY, Joo YD, Park JH, Lee KH; Korean Society of Blood and Marrow Transplantation. Kim H, et al. Among authors: joo yd. Biol Blood Marrow Transplant. 2011 Sep;17(9):1289-98. doi: 10.1016/j.bbmt.2010.12.715. Epub 2011 Jan 8. Biol Blood Marrow Transplant. 2011. PMID: 21220035 Free article.
87 results